Every article, report, and earnings note where SMMT appears.
Summit Therapeutics is a high-risk oncology biotech whose fate hinges on ivonescimab and upcoming FDA/regulatory decisions. Strong Phase III data support the story, but heavy cash burn, no revenue, and dilution risk keep the stock at Hold.
Summit Therapeutics Inc. (SMMT) rises after AstraZeneca’s $2 billion strategic investment sparked heavy trading and renewed confidence in the company’s lead cancer drug, ivonescimab. The move highlights investor enthusiasm for the partnership, but the stock still carries biotech execution, clinical, and dilution risk.
Summit Therapeutics Inc. (SMMT) jumps after AstraZeneca announced a $2 billion strategic investment and trial collaboration tied to ivonescimab. The deal boosts funding, validates the pipeline, and lifted shares in extended-hours trading, though clinical, dilution, and valuation risks remain for investors.
Summit Therapeutics Inc. (SMMT) jumps after AstraZeneca announced a $2 billion strategic investment and new clinical collaboration around ivonescimab. The move lifts shares toward the deal’s implied valuation, but investors still face biotech volatility, loss-making fundamentals, and execution risk tied to trial results.
Summit Therapeutics Inc. (SMMT) climbs after fresh Phase III ivonescimab results strengthened the drug's oncology case. The move follows an overall survival benefit in biliary tract cancer and comes ahead of key FDA and conference milestones that could further shape the stock's outlook.
Summit Therapeutics is trading like the financing scare already came and went. The rebound says the market cares more about ivonescimab's November 14, 2026 FDA clock and funded Phase III runway than a headline offering that never even closed.
Summit’s financing headline looks ugly, but the insider tape says management is still leaning into ivonescimab rather than backing away from it. When co-CEOs and the CFO buy more than $100 million of stock right into a raise, dilution stops looking like the whole story.
Summit Therapeutics is trading like ivonescimab broke, but the key catalyst is still on the calendar. The market is hammering SMMT for financing and credibility risk, and that distinction matters because those are fixable problems while the November 2026 FDA decision remains alive.
Summit Therapeutics Inc. (SMMT) drops sharply as investors reassess confidence in ivonescimab after fresh scrutiny of the drug’s trial data. Heavy volume suggests a catalyst-driven selloff, even after the company highlighted positive HARMONi-6 overall survival results in first-line squamous NSCLC.
Summit Therapeutics Inc. (SMMT) tumbles after its first-quarter 2026 results and operational update, as investors react to a wider loss, heavy biotech spending, and the risks tied to its single lead asset, ivonescimab. Volume surged above average as traders repriced the stock.
Summit Therapeutics Inc. (SMMT) drops sharply as momentum cools after a strong run, with no fresh catalyst to support buyers. High short interest and biotech valuation risk are amplifying the move, even as investors wait for the next ivonescimab milestone.
Generate an AI-powered research report — grades, price targets, financials, and chart analysis on demand.
Generate SMMT ReportCancel anytime